
Brain Ischemia Market
Description
Brain Ischemia Market Report and Forecast 2024-2032
The brain ischemia market was valued at USD 622.3 million by 2023 driven by the increasing incidence of ischemic strokes and the rising demand for minimally invasive therapies. It is projected to grow at a CAGR of 6.1% during the forecast period of 2024-2032, and is likely to gain a value of USD 1397 million by 2032.
Brain Ischemia Market Analysis
Brain ischemia, also known as cerebral ischemia, occurs when there is insufficient blood flow to the brain, leading to inadequate oxygen and nutrient supply. This condition can result from a blood clot, embolism, or narrowed arteries and may lead to severe consequences such as stroke or brain damage. Treatments aim to restore blood flow and minimise neurological damage, often involving medications like blood thinners or surgical interventions. Early diagnosis and treatment are critical in reducing long-term effects on cognitive and motor functions.
Market Drivers
Rising Incidence of Stroke: The increasing prevalence of stroke, a leading cause of brain ischemia, is driving demand for treatments. This surge is largely due to an ageing global population and rising incidences of risk factors such as hypertension and diabetes.
Technological Advancements in Diagnostics: Advances in imaging technologies, such as MRI and CT scans, have significantly improved the early diagnosis of brain ischemia, enhancing treatment outcomes and contributing to market growth.
Increasing Healthcare Awareness: Growing public awareness about brain ischemia and its early symptoms, supported by government and health campaigns, is driving patients to seek medical intervention earlier, boosting the demand for treatments.
Rising Geriatric Population: As the global elderly population increases, the risk of age-related conditions like brain ischemia grows, creating higher demand for effective treatments, particularly in developed countries with advanced healthcare systems.
Development of Novel Therapeutics: Ongoing research into innovative drug therapies and interventions, such as neuroprotective agents and thrombolytics, offers new avenues for the treatment of brain ischemia, driving market expansion.
Challenges
High Cost of Treatment: Brain ischemia treatments, especially surgical interventions and advanced therapies, are often expensive, limiting accessibility, particularly in low-income regions and developing economies.
Limited Access to Healthcare: Many parts of the world, especially rural and underdeveloped regions, face significant challenges in accessing timely healthcare for brain ischemia due to inadequate infrastructure and a shortage of trained medical professionals.
Post-Surgical Complications: Surgical interventions for brain ischemia, such as carotid endarterectomy, carry risks of complications, including infection, stroke recurrence, and neurological damage, which may hinder patient uptake of these treatments.
Low Awareness in Developing Regions: Despite growing awareness in developed nations, many developing countries still lack sufficient public knowledge about brain ischemia, leading to delayed diagnosis and treatment, which impacts market growth.
Stringent Regulatory Approvals: The stringent regulations and lengthy approval processes for new drugs and medical devices used in brain ischemia treatment pose significant barriers to market entry for pharmaceutical companies.
Future Opportunities
Development of Neuroprotective Agents: There is a growing opportunity for pharmaceutical companies to develop neuroprotective agents that minimise brain damage during ischemic events, potentially transforming the treatment landscape.
Expansion into Emerging Markets: Increasing investment in healthcare infrastructure in emerging economies presents opportunities for market growth, particularly in regions like Asia-Pacific and Latin America, where healthcare access is improving.
Telemedicine and Remote Monitoring: The rise of telemedicine and digital healthcare technologies provides opportunities for better management and early detection of brain ischemia, especially in remote or underserved areas.
Partnerships and Collaborations: Collaborations between pharmaceutical companies, healthcare institutions, and research organisations can accelerate the development of novel therapies and improve market access, creating opportunities for innovation.
Focus on Preventative Care: Increased emphasis on preventative healthcare, such as managing hypertension and diabetes, presents opportunities to reduce the risk of brain ischemia, thereby driving demand for early intervention therapies and diagnostic tools.
Brain Ischemia Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Brain Ischemia Market Segmentation
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by End User
Market Breakup by Region
Brain Ischemia Market Competitive Landscape
The competitive landscape in the brain ischemia market features key players such as Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Novartis AG, Abbott, Johnson & Johnson Services Inc., and AstraZeneca. These companies focus on developing innovative drugs and surgical interventions to treat brain ischemia, leveraging research collaborations and technological advancements. Recent developments include the introduction of novel neuroprotective agents and minimally invasive surgeries, helping to improve patient outcomes and expand market reach.
Key Questions Answered in the Report
What are the main drivers of the brain ischemia market?
How do advanced imaging technologies impact the treatment of brain ischemia?
What challenges are healthcare providers facing in brain ischemia management?
How are emerging markets influencing the growth of the brain ischemia market?
What opportunities exist for developing new neuroprotective agents?
How are surgical interventions evolving in the treatment of brain ischemia?
What role do beta blockers and angiotensin-converting enzyme inhibitors play in treating brain ischemia?
How does the growing elderly population impact the demand for brain ischemia treatments?
How are healthcare providers integrating AI into brain ischemia diagnostics?
What are the key trends in minimally invasive brain ischemia treatments?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the brain ischemia market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the brain ischemia market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the brain ischemia industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The brain ischemia market was valued at USD 622.3 million by 2023 driven by the increasing incidence of ischemic strokes and the rising demand for minimally invasive therapies. It is projected to grow at a CAGR of 6.1% during the forecast period of 2024-2032, and is likely to gain a value of USD 1397 million by 2032.
Brain Ischemia Market Analysis
Brain ischemia, also known as cerebral ischemia, occurs when there is insufficient blood flow to the brain, leading to inadequate oxygen and nutrient supply. This condition can result from a blood clot, embolism, or narrowed arteries and may lead to severe consequences such as stroke or brain damage. Treatments aim to restore blood flow and minimise neurological damage, often involving medications like blood thinners or surgical interventions. Early diagnosis and treatment are critical in reducing long-term effects on cognitive and motor functions.
Market Drivers
Rising Incidence of Stroke: The increasing prevalence of stroke, a leading cause of brain ischemia, is driving demand for treatments. This surge is largely due to an ageing global population and rising incidences of risk factors such as hypertension and diabetes.
Technological Advancements in Diagnostics: Advances in imaging technologies, such as MRI and CT scans, have significantly improved the early diagnosis of brain ischemia, enhancing treatment outcomes and contributing to market growth.
Increasing Healthcare Awareness: Growing public awareness about brain ischemia and its early symptoms, supported by government and health campaigns, is driving patients to seek medical intervention earlier, boosting the demand for treatments.
Rising Geriatric Population: As the global elderly population increases, the risk of age-related conditions like brain ischemia grows, creating higher demand for effective treatments, particularly in developed countries with advanced healthcare systems.
Development of Novel Therapeutics: Ongoing research into innovative drug therapies and interventions, such as neuroprotective agents and thrombolytics, offers new avenues for the treatment of brain ischemia, driving market expansion.
Challenges
High Cost of Treatment: Brain ischemia treatments, especially surgical interventions and advanced therapies, are often expensive, limiting accessibility, particularly in low-income regions and developing economies.
Limited Access to Healthcare: Many parts of the world, especially rural and underdeveloped regions, face significant challenges in accessing timely healthcare for brain ischemia due to inadequate infrastructure and a shortage of trained medical professionals.
Post-Surgical Complications: Surgical interventions for brain ischemia, such as carotid endarterectomy, carry risks of complications, including infection, stroke recurrence, and neurological damage, which may hinder patient uptake of these treatments.
Low Awareness in Developing Regions: Despite growing awareness in developed nations, many developing countries still lack sufficient public knowledge about brain ischemia, leading to delayed diagnosis and treatment, which impacts market growth.
Stringent Regulatory Approvals: The stringent regulations and lengthy approval processes for new drugs and medical devices used in brain ischemia treatment pose significant barriers to market entry for pharmaceutical companies.
Future Opportunities
Development of Neuroprotective Agents: There is a growing opportunity for pharmaceutical companies to develop neuroprotective agents that minimise brain damage during ischemic events, potentially transforming the treatment landscape.
Expansion into Emerging Markets: Increasing investment in healthcare infrastructure in emerging economies presents opportunities for market growth, particularly in regions like Asia-Pacific and Latin America, where healthcare access is improving.
Telemedicine and Remote Monitoring: The rise of telemedicine and digital healthcare technologies provides opportunities for better management and early detection of brain ischemia, especially in remote or underserved areas.
Partnerships and Collaborations: Collaborations between pharmaceutical companies, healthcare institutions, and research organisations can accelerate the development of novel therapies and improve market access, creating opportunities for innovation.
Focus on Preventative Care: Increased emphasis on preventative healthcare, such as managing hypertension and diabetes, presents opportunities to reduce the risk of brain ischemia, thereby driving demand for early intervention therapies and diagnostic tools.
Brain Ischemia Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Increasing Use of Advanced Imaging Technologies
- Development of Thrombolytic Drugs
- Emergence of Minimally Invasive Surgeries
- Growth in Rehabilitation Services
- Focus on Personalised Medicine
- Use of AI in Diagnostics
Brain Ischemia Market Segmentation
Market Breakup by Type
- Focal Brain Ischemia
- Global Brain Ischemia
Market Breakup by Treatment Type
- Surgery
- Drugs
- Beta Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Academic and Research Institutes
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Brain Ischemia Market Competitive Landscape
The competitive landscape in the brain ischemia market features key players such as Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Novartis AG, Abbott, Johnson & Johnson Services Inc., and AstraZeneca. These companies focus on developing innovative drugs and surgical interventions to treat brain ischemia, leveraging research collaborations and technological advancements. Recent developments include the introduction of novel neuroprotective agents and minimally invasive surgeries, helping to improve patient outcomes and expand market reach.
Key Questions Answered in the Report
What are the main drivers of the brain ischemia market?
How do advanced imaging technologies impact the treatment of brain ischemia?
What challenges are healthcare providers facing in brain ischemia management?
How are emerging markets influencing the growth of the brain ischemia market?
What opportunities exist for developing new neuroprotective agents?
How are surgical interventions evolving in the treatment of brain ischemia?
What role do beta blockers and angiotensin-converting enzyme inhibitors play in treating brain ischemia?
How does the growing elderly population impact the demand for brain ischemia treatments?
How are healthcare providers integrating AI into brain ischemia diagnostics?
What are the key trends in minimally invasive brain ischemia treatments?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the brain ischemia market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the brain ischemia market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the brain ischemia industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Brain Ischemia Market Overview – 8 Major Markets
- 3.1 Brain Ischemia Market Historical Value (2018-2024)
- 3.2 Brain Ischemia Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Brain Ischemia Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Brain Ischemia Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Brain Ischemia Market Landscape – 8 Major Markets
- 8.1 Brain Ischemia Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Brain Ischemia Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Treatment Type
- 9 Brain Ischemia Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Brain Ischemia Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Brain Ischemia Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Brain Ischemia Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Focal Brain Ischemia
- 12.1.3 Global Brain Ischemia
- 12.2 Brain Ischemia Market (2018-2034) by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Surgery
- 12.2.3 Drugs
- 12.2.3.1 Beta Blockers
- 12.2.3.2 Angiotensin-Converting Enzyme Inhibitors
- 12.2.3.3 Others
- 12.3 Brain Ischemia Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Specialty Clinics
- 12.3.4 Academic & Research Institutes
- 12.3.5 Others
- 12.4 Brain Ischemia Market (2018-2034) by Country
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States Brain Ischemia Market (2018-2034)
- 13.1 United States Brain Ischemia Market Historical Value (2018-2024)
- 13.2 United States Brain Ischemia Market Forecast Value (2025-2034)
- 13.3 United States Brain Ischemia Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Focal Brain Ischemia
- 13.3.3 Global Brain Ischemia
- 13.4 United States Brain Ischemia Market (2018-2034) by Treatment Type
- 13.4.1 Market Overview
- 13.4.2 Surgery
- 13.4.3 Drugs
- 13.4.3.1 Beta Blockers
- 13.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 13.4.3.3 Others
- 13.5 United States Brain Ischemia Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Specialty Clinics
- 13.5.4 Academic & Research Institutes
- 13.5.5 Others
- 14 United Kingdom Brain Ischemia Market (2018-2034)
- 14.1 United Kingdom Brain Ischemia Market Historical Value (2018-2024)
- 14.2 United Kingdom Brain Ischemia Market Forecast Value (2025-2034)
- 14.3 United Kingdom Brain Ischemia Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Focal Brain Ischemia
- 14.3.3 Global Brain Ischemia
- 14.4 United Kingdom Brain Ischemia Market (2018-2034) by Treatment Type
- 14.4.1 Market Overview
- 14.4.2 Surgery
- 14.4.3 Drugs
- 14.4.3.1 Beta Blockers
- 14.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 14.4.3.3 Others
- 14.5 United Kingdom Brain Ischemia Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Specialty Clinics
- 14.5.4 Academic & Research Institutes
- 14.5.5 Others
- 15 Germany Brain Ischemia Market (2018-2034)
- 15.1 Germany Brain Ischemia Market Historical Value (2018-2024)
- 15.2 Germany Brain Ischemia Market Forecast Value (2025-2034)
- 15.3 Germany Brain Ischemia Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Focal Brain Ischemia
- 15.3.3 Global Brain Ischemia
- 15.4 Germany Brain Ischemia Market (2018-2034) by Treatment Type
- 15.4.1 Market Overview
- 15.4.2 Surgery
- 15.4.3 Drugs
- 15.4.3.1 Beta Blockers
- 15.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 15.4.3.3 Others
- 15.5 Germany Brain Ischemia Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Specialty Clinics
- 15.5.4 Academic & Research Institutes
- 15.5.5 Others
- 16 France Brain Ischemia Market (2018-2034)
- 16.1 France Brain Ischemia Market Historical Value (2018-2024)
- 16.2 France Brain Ischemia Market Forecast Value (2025-2034)
- 16.3 France Brain Ischemia Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Focal Brain Ischemia
- 16.3.3 Global Brain Ischemia
- 16.4 France Brain Ischemia Market (2018-2034) by Treatment Type
- 16.4.1 Market Overview
- 16.4.2 Surgery
- 16.4.3 Drugs
- 16.4.3.1 Beta Blockers
- 16.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 16.4.3.3 Others
- 16.5 France Brain Ischemia Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Specialty Clinics
- 16.5.4 Academic & Research Institutes
- 16.5.5 Others
- 17 Italy Brain Ischemia Market (2018-2034)
- 17.1 Italy Brain Ischemia Market Historical Value (2018-2024)
- 17.2 Italy Brain Ischemia Market Forecast Value (2025-2034)
- 17.3 Italy Brain Ischemia Market (2018-2034) by Type
- 17.3.1 Market Overview
- 17.3.2 Focal Brain Ischemia
- 17.3.3 Global Brain Ischemia
- 17.4 Italy Brain Ischemia Market (2018-2034) by Treatment Type
- 17.4.1 Market Overview
- 17.4.2 Surgery
- 17.4.3 Drugs
- 17.4.3.1 Beta Blockers
- 17.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 17.4.3.3 Others
- 17.5 Italy Brain Ischemia Market (2018-2034) by End User
- 17.5.1 Market Overview
- 17.5.2 Hospitals
- 17.5.3 Specialty Clinics
- 17.5.4 Academic & Research Institutes
- 17.5.5 Others
- 18 Spain Brain Ischemia Market (2018-2034)
- 18.1 Spain Brain Ischemia Market Historical Value (2018-2024)
- 18.2 Spain Brain Ischemia Market Forecast Value (2025-2034)
- 18.3 Spain Brain Ischemia Market (2018-2034) by Type
- 18.3.1 Market Overview
- 18.3.2 Focal Brain Ischemia
- 18.3.3 Global Brain Ischemia
- 18.4 Spain Brain Ischemia Market (2018-2034) by Treatment Type
- 18.4.1 Market Overview
- 18.4.2 Surgery
- 18.4.3 Drugs
- 18.4.3.1 Beta Blockers
- 18.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 18.4.3.3 Others
- 18.5 Spain Brain Ischemia Market (2018-2034) by End User
- 18.5.1 Market Overview
- 18.5.2 Hospitals
- 18.5.3 Specialty Clinics
- 18.5.4 Academic & Research Institutes
- 18.5.5 Others
- 19 Japan Brain Ischemia Market
- 19.1 Japan Brain Ischemia Market Historical Value (2018-2024)
- 19.2 Japan Brain Ischemia Market Forecast Value (2025-2034)
- 19.3 Japan Brain Ischemia Market (2018-2034) by Type
- 19.3.1 Market Overview
- 19.3.2 Focal Brain Ischemia
- 19.3.3 Global Brain Ischemia
- 19.4 Japan Brain Ischemia Market (2018-2034) by Treatment Type
- 19.4.1 Market Overview
- 19.4.2 Surgery
- 19.4.3 Drugs
- 19.4.3.1 Beta Blockers
- 19.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 19.4.3.3 Others
- 19.5 Japan Brain Ischemia Market (2018-2034) by End User
- 19.5.1 Market Overview
- 19.5.2 Hospitals
- 19.5.3 Specialty Clinics
- 19.5.4 Academic & Research Institutes
- 19.5.5 Others
- 20 India Brain Ischemia Market
- 20.1 India Brain Ischemia Market (2018-2034) Historical Value (2018-2024)
- 20.2 India Brain Ischemia Market (2018-2034) Forecast Value (2025-2034)
- 20.3 India Brain Ischemia Market (2018-2034) by Type
- 20.3.1 Market Overview
- 20.3.2 Focal Brain Ischemia
- 20.3.3 Global Brain Ischemia
- 20.4 India Brain Ischemia Market (2018-2034) by Treatment Type
- 20.4.1 Market Overview
- 20.4.2 Surgery
- 20.4.3 Drugs
- 20.4.3.1 Beta Blockers
- 20.4.3.2 Angiotensin-Converting Enzyme Inhibitors
- 20.4.3.3 Others
- 20.5 India Brain Ischemia Market (2018-2034) by End User
- 20.5.1 Market Overview
- 20.5.2 Hospitals
- 20.5.3 Specialty Clinics
- 20.5.4 Academic & Research Institutes
- 20.5.5 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 22.7 Analysis by Key Players
- 23 Clinical Trials and Pipeline Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 23.6 Drug Pipeline Assessment
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Type of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Type of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share by Top 5 Companies
- 27.2 Bristol Myers Squibb
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Companies News and Developments
- 27.2.5 Certifications
- 27.3 Boehringer Ingelheim International GmbH
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Companies News and Developments
- 27.3.5 Certifications
- 27.4 Novartis AG
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Companies News and Developments
- 27.4.5 Certifications
- 27.5 Abbott
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Companies News and Developments
- 27.5.5 Certifications
- 27.6 Johnson & Johnson Services Inc.
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Companies News and Developments
- 27.6.5 Certifications
- 27.7 AstraZeneca
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Companies News and Developments
- 27.7.5 Certifications
- 28 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.